Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1986 1
1990 1
1997 1
1998 2
1999 1
2001 1
2002 1
2003 3
2004 1
2005 1
2008 5
2009 3
2010 4
2011 1
2013 2
2014 1
2015 1
2016 1
2017 2
2018 2
2019 2
2020 4
2021 3
2022 5
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Fizazi K, et al. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. N Engl J Med. 2023. PMID: 36795891 Free PMC article. Clinical Trial.
RESULTS: Of the 4855 patients who had undergone prescreening or screening, 270 were assigned to receive rucaparib and 135 to receive a control medication (intention-to-treat population); in the two groups, 201 patients and 101 patients, respectively, had a BRCA alteration. At 62 …
RESULTS: Of the 4855 patients who had undergone prescreening or screening, 270 were assigned to receive rucaparib and 135 to receive a contr …
Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.
Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart J, Erro ME, Abraira L, Moris G, Monros-Giménez L, Corral-Corral Í, Montejo C, Toledo M, Bataller L, Secondi G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Graus F, Dalmau J; Spanish Herpes Simplex Encephalitis Study Group. Armangue T, et al. Among authors: juan m. Lancet Neurol. 2018 Sep;17(9):760-772. doi: 10.1016/S1474-4422(18)30244-8. Epub 2018 Jul 23. Lancet Neurol. 2018. PMID: 30049614 Free PMC article.
In the prospective observational part of this study, we included patients with herpes simplex encephalitis diagnosed by neurologists, paediatricians, or infectious disease specialists in 19 secondary and tertiary Spanish centres (Cohort A). Outpatient follow-up was at 2, 6, and 1 …
In the prospective observational part of this study, we included patients with herpes simplex encephalitis diagnosed by neurologists, paedia …
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: juan m. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060 Free article.
At the planned interim analysis (cutoff date Oct 20, 2021), with a median follow-up of 12.1 months (IQR 9.1-13.5), overall response during the first 100 days from infusion was 100%, including 24 (80%) of 30 patients with a very good partial response or better (15 [50%] wit …
At the planned interim analysis (cutoff date Oct 20, 2021), with a median follow-up of 12.1 months (IQR 9.1-13.5), overall response d …
Expected impact of immunomodulatory agents during pregnancy: A newborn's perspective.
Luo Y, Acevedo D, Baños N, Pluma A, Castellanos-Moreira R, Moreno E, Rodríguez-García S, Deyà-Martínez A, García-García A, Quesada-Masachs E, Torres M, Casellas M, Grados D, Martí-Castellote C, Antón J, Vlagea A, Juan M, Esteve-Solé A, Alsina L. Luo Y, et al. Among authors: juan m. Pediatr Allergy Immunol. 2023 Feb;34(2):e13911. doi: 10.1111/pai.13911. Pediatr Allergy Immunol. 2023. PMID: 36825745 Review.
Most of the biological therapy have a prolonged half-life in newborn's blood, being detectable in infants up to 12 months after birth (usually 6-9 months). The use of immunomodulators during pregnancy is gaining global interest. ...
Most of the biological therapy have a prolonged half-life in newborn's blood, being detectable in infants up to 12 months after birth …
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Bueno C, Barrera S, Bataller A, Ortiz-Maldonado V, Elliot N, O'Byrne S, Wang G, Rovira M, Gutierrez-Agüera F, Trincado JL, González-González M, Morgades M, Sorigué M, Bárcena P, Zanetti SR, Torrebadell M, Vega-Garcia N, Rives S, Mallo M, Sole F, Mead AJ, Roberts I, Thongjuea S, Psaila B, Juan M, Delgado J, Urbano-Ispizúa A, Ribera JM, Orfao A, Roy A, Menendez P. Bueno C, et al. Among authors: juan m. Blood. 2022 Jul 7;140(1):38-44. doi: 10.1182/blood.2021014840. Blood. 2022. PMID: 35421218 Free PMC article.
The median of CD34+CD19-CD22+ cells before treatment was threefold higher in patients in whom B-ALL relapsed after CD19-directed immunotherapy (median follow-up, 24 months). Fluorescence in situ hybridization analysis in flow-sorted cell populations and xenograft modeling …
The median of CD34+CD19-CD22+ cells before treatment was threefold higher in patients in whom B-ALL relapsed after CD19-directed immunothera …
Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients.
González J, de Batlle J, Benítez ID, Torres G, Santisteve S, Targa ADS, Gort-Paniello C, Moncusí-Moix A, Aguilà M, Seck F, Ceccato A, Ferrer R, Motos A, Riera J, Fernández L, Menéndez R, Lorente JÁ, Peñuelas O, Garcia-Gasulla D, Peñasco Y, Ricart P, Abril Palomares E, Aguilera L, Rodríguez A, Boado Varela MV, Beteré B, Pozo-Laderas JC, Solé-Violan J, Salvador-Adell I, Novo MA, Barberán J, Amaya Villar R, Garnacho-Montero J, Gómez JM, Blandino Ortiz A, Tamayo Lomas L, Úbeda A, Catalán-González M, Sánchez-Miralles A, Martínez Varela I, Jorge García RN, Franco N, Gumucio-Sanguino VD, Bustamante-Munguira E, Valdivia LJ, Caballero J, Gallego E, Rodríguez C, Castellanos-Ortega Á, Trenado J, Marin-Corral J, Albaiceta GM, de la Torre MDC, Loza-Vázquez A, Vidal P, Añón JM, Carbajales Pérez C, Sagredo V, Carbonell N, Socias L, Barberà C, Estella A, Diaz E, de Gonzalo-Calvo D, Torres A, Barbé F; CIBERESUCICOVID Project. González J, et al. Arch Bronconeumol. 2023 Apr;59(4):205-215. doi: 10.1016/j.arbres.2022.12.017. Epub 2023 Jan 7. Arch Bronconeumol. 2023. PMID: 36690515 Free PMC article.
RESULTS: The median [p(25)-p(75)] time from discharge to follow-up was 3.57 [2.77-4.92] months. Median age was 60 [53-67] years, 27.8% women. The mean (SD) percentage of predicted diffusing lung capacity for carbon monoxide (D(LCO)) at follow-up was 72.02 (18.33)% predicte …
RESULTS: The median [p(25)-p(75)] time from discharge to follow-up was 3.57 [2.77-4.92] months. Median age was 60 [53-67] years, 27.8 …
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.
Egri N, Calderón H, Martinez R, Vazquez M, Gómez-Caverzaschi V, Pascal M, Araújo O, Juan M, González-Navarro EA, Hernández-Rodríguez J. Egri N, et al. Among authors: juan m. Front Immunol. 2023 Apr 27;14:1146841. doi: 10.3389/fimmu.2023.1146841. eCollection 2023. Front Immunol. 2023. PMID: 37180097 Free PMC article.
Nine (90%) patients developed mild COVID-19 after a median of 7 months of the third dose. CONCLUSION: Rituximab in patients with autoimmune diseases reduces humoral responses but does not avoid the development of T cell responses to SARS-CoV-2 vaccination, which remain pre …
Nine (90%) patients developed mild COVID-19 after a median of 7 months of the third dose. CONCLUSION: Rituximab in patients with auto …
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
García-Corbacho J, Indacochea A, González Navarro AE, Victoria I, Moreno D, Pesántez D, Angelats L, Modrego-Sanchez A, Sanfeliu E, Castillo O, Blasco P, Mezquita L, Viñolas N, Nogué M, Galván P, Adamo B, Basté N, Sauri T, Juan M, Prat A, Schettini F. García-Corbacho J, et al. Among authors: juan m. Cancer Immunol Immunother. 2023 Jun;72(6):1709-1723. doi: 10.1007/s00262-022-03360-9. Epub 2023 Jan 10. Cancer Immunol Immunother. 2023. PMID: 36625938 Free PMC article.
Associations with overall response rates (ORR), durable clinical benefit (DCB), progression-free survival (PFS) and overall survival (OS) were performed with univariable/multivariable logistic and Cox regressions, where appropriate. At a median follow-up of 26.9 months, me …
Associations with overall response rates (ORR), durable clinical benefit (DCB), progression-free survival (PFS) and overall survival (OS) we …
Single-cycle rituximab-induced immunologic changes in children: Enhanced in neuroimmunologic disease?
Deyà-Martínez A, Gordón Y, Molina-Anguita C, Vlagea A, Piquer M, Juan M, Esteve-Solé A, Antón J, Madrid Á, García-García A, Plaza AM, Armangue T, Alsina L. Deyà-Martínez A, et al. Among authors: juan m. Neurol Neuroimmunol Neuroinflamm. 2020 May 6;7(4):e724. doi: 10.1212/NXI.0000000000000724. Print 2020 Jul. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32376706 Free PMC article.
Patients were clinically and immunologically followed up every 3 months. Only patients having received a single cycle of RTX and with a follow-up greater than 12 months were included in the analysis of persistent dysgammaglobulinemia. ...Median age at RTX treatment …
Patients were clinically and immunologically followed up every 3 months. Only patients having received a single cycle of RTX and with …
Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma.
Oliver-Caldés A, Español-Rego M, Zabaleta A, Gonzalez-Calle V, Navarro-Velázquez S, Inoges S, López-Díaz de Cerio A, Cabañas V, López-Muñoz N, Rodriguez-Otero P, Reguera-Ortega JL, Moreno DF, Martínez-Cibrian N, López-Corral L, Pérez-Amill L, Martin-Antonio B, Rosinol L, Cid J, Tovar N, Saez-Peñataro J, Lopez-Parra M, Olesti E, Guillen E, Varea S, Rodríguez-Lobato LG, Battram AM, Gonzalez-Perez MS, Sanchez-Salinas A, González-Navarro A, Ortiz-Maldonado V, Delgado J, Prosper F, Juan M, Martinez-Lopez J, Moraleda JM, Mateos MV, Urbano-Ispizua A, Paiva B, Pascal M, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: juan m. Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-23-3759. Online ahead of print. Clin Cancer Res. 2024. PMID: 38466644
RESULTS: At cutoff date March 17th 2023, with a median follow-up of 23.1 months (95%CI 9.2-37.1), overall response rate in the first 3 months was 95% (95%CI 89.5-100); cytokine release syndrome (CRS) was observed in 90% of patients (5% grades3) and grade 1 immune ef …
RESULTS: At cutoff date March 17th 2023, with a median follow-up of 23.1 months (95%CI 9.2-37.1), overall response rate in the first …
56 results